Advocacy groups and other stakeholders argue that for too long, clinical trials have lacked participants from racial minorities and other socially disadvantaged groups. Last month, the US Congress passed a new law that could begin reversing this trend.
A provision in the omnibus spending package passed in December, “The Food and Drug Omnibus Reform Act (FDORA),” requires sponsors of most drug and device clinical studies to include...